Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate

Maria Coco, Daniel Glicklich, Marie Claude Faugere, Larry Burris, Istvan Bognar, Peter Durkin, Vivian Tellis, Stuart M. Greenstein, Richard Schechner, Katherine Figueroa, Patricia McDonough, Guodong Wang, Hartmut Malluche

Research output: Contribution to journalArticle

190 Citations (Scopus)

Abstract

Renal transplant recipients are at risk of developing bone abnormalities that result in bone loss and bone fractures. These are related to underlying renal osteodystrophy, hypophosphatemia, and immunosuppressive treatment regimen. Although bisphosphonates are useful in ameliorating bone mineral loss after transplantation, it is not known whether their use in renal transplant patients leads to excessive suppression of bone turnover and increased incidence of adynamic bone disease. A randomized, prospective, controlled, clinical trial was conducted using the bisphosphonate pamidronate intravenously in patients with new renal transplants. Treatment subjects (PAM) received pamidronate with vitamin D and calcium at baseline and at months 1, 2, 3, and 6. Control (CON) subjects received vitamin D and calcium only. During months 6 to 12, the subjects were observed without pamidronate treatment. Biochemical parameters of bone turnover were obtained monthly and, bone mineral density (BMD) was obtained at baseline and months 6 and 12. Bone biopsies for mineralized bone histology were obtained at baseline and at 6 mo in a subgroup of subjects who underwent scheduled living donor transplantation. PAM preserved bone mass at 6 and 12 mo as measured by bone densitometry and histomorphometry. CON had decreased vertebral BMD at 6 and 12 mo (4.8 ± 0.08 and 6.1 ± 0.09%, respectively). Biochemical parameters of bone turnover were similar in both groups at 6 and 12 mo. Bone histology revealed low turnover bone disease in 50% of the patients at baseline. At 6 mo, all of PAM had adynamic bone disease, whereas 50% of CON continued to have or developed decreased bone turnover. Pamidronate preserved vertebral BMD during treatment and 6 mo after cessation of treatment. Pamidronate treatment was associated with development of adynamic bone histology. Whether an improved BMD with adynamic bone histology is useful in maintaining long-term bone health in renal transplant recipients requires further study.

Original languageEnglish (US)
Pages (from-to)2669-2676
Number of pages8
JournalJournal of the American Society of Nephrology
Volume14
Issue number10
DOIs
StatePublished - Oct 1 2003

Fingerprint

pamidronate
Kidney
Bone and Bones
Bone Remodeling
Bone Density
Bone Diseases
Histology
Diphosphonates
Vitamin D
Transplantation
Transplant Recipients
Chronic Kidney Disease-Mineral and Bone Disorder
Calcium
Hypophosphatemia
Transplants
Therapeutics
Withholding Treatment

ASJC Scopus subject areas

  • Nephrology

Cite this

Prevention of bone loss in renal transplant recipients : A prospective, randomized trial of intravenous pamidronate. / Coco, Maria; Glicklich, Daniel; Faugere, Marie Claude; Burris, Larry; Bognar, Istvan; Durkin, Peter; Tellis, Vivian; Greenstein, Stuart M.; Schechner, Richard; Figueroa, Katherine; McDonough, Patricia; Wang, Guodong; Malluche, Hartmut.

In: Journal of the American Society of Nephrology, Vol. 14, No. 10, 01.10.2003, p. 2669-2676.

Research output: Contribution to journalArticle

Coco, M, Glicklich, D, Faugere, MC, Burris, L, Bognar, I, Durkin, P, Tellis, V, Greenstein, SM, Schechner, R, Figueroa, K, McDonough, P, Wang, G & Malluche, H 2003, 'Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate', Journal of the American Society of Nephrology, vol. 14, no. 10, pp. 2669-2676. https://doi.org/10.1097/01.ASN.0000087092.53894.80
Coco, Maria ; Glicklich, Daniel ; Faugere, Marie Claude ; Burris, Larry ; Bognar, Istvan ; Durkin, Peter ; Tellis, Vivian ; Greenstein, Stuart M. ; Schechner, Richard ; Figueroa, Katherine ; McDonough, Patricia ; Wang, Guodong ; Malluche, Hartmut. / Prevention of bone loss in renal transplant recipients : A prospective, randomized trial of intravenous pamidronate. In: Journal of the American Society of Nephrology. 2003 ; Vol. 14, No. 10. pp. 2669-2676.
@article{5a72200b99304f87937cca88c688d375,
title = "Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate",
abstract = "Renal transplant recipients are at risk of developing bone abnormalities that result in bone loss and bone fractures. These are related to underlying renal osteodystrophy, hypophosphatemia, and immunosuppressive treatment regimen. Although bisphosphonates are useful in ameliorating bone mineral loss after transplantation, it is not known whether their use in renal transplant patients leads to excessive suppression of bone turnover and increased incidence of adynamic bone disease. A randomized, prospective, controlled, clinical trial was conducted using the bisphosphonate pamidronate intravenously in patients with new renal transplants. Treatment subjects (PAM) received pamidronate with vitamin D and calcium at baseline and at months 1, 2, 3, and 6. Control (CON) subjects received vitamin D and calcium only. During months 6 to 12, the subjects were observed without pamidronate treatment. Biochemical parameters of bone turnover were obtained monthly and, bone mineral density (BMD) was obtained at baseline and months 6 and 12. Bone biopsies for mineralized bone histology were obtained at baseline and at 6 mo in a subgroup of subjects who underwent scheduled living donor transplantation. PAM preserved bone mass at 6 and 12 mo as measured by bone densitometry and histomorphometry. CON had decreased vertebral BMD at 6 and 12 mo (4.8 ± 0.08 and 6.1 ± 0.09{\%}, respectively). Biochemical parameters of bone turnover were similar in both groups at 6 and 12 mo. Bone histology revealed low turnover bone disease in 50{\%} of the patients at baseline. At 6 mo, all of PAM had adynamic bone disease, whereas 50{\%} of CON continued to have or developed decreased bone turnover. Pamidronate preserved vertebral BMD during treatment and 6 mo after cessation of treatment. Pamidronate treatment was associated with development of adynamic bone histology. Whether an improved BMD with adynamic bone histology is useful in maintaining long-term bone health in renal transplant recipients requires further study.",
author = "Maria Coco and Daniel Glicklich and Faugere, {Marie Claude} and Larry Burris and Istvan Bognar and Peter Durkin and Vivian Tellis and Greenstein, {Stuart M.} and Richard Schechner and Katherine Figueroa and Patricia McDonough and Guodong Wang and Hartmut Malluche",
year = "2003",
month = "10",
day = "1",
doi = "10.1097/01.ASN.0000087092.53894.80",
language = "English (US)",
volume = "14",
pages = "2669--2676",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "10",

}

TY - JOUR

T1 - Prevention of bone loss in renal transplant recipients

T2 - A prospective, randomized trial of intravenous pamidronate

AU - Coco, Maria

AU - Glicklich, Daniel

AU - Faugere, Marie Claude

AU - Burris, Larry

AU - Bognar, Istvan

AU - Durkin, Peter

AU - Tellis, Vivian

AU - Greenstein, Stuart M.

AU - Schechner, Richard

AU - Figueroa, Katherine

AU - McDonough, Patricia

AU - Wang, Guodong

AU - Malluche, Hartmut

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Renal transplant recipients are at risk of developing bone abnormalities that result in bone loss and bone fractures. These are related to underlying renal osteodystrophy, hypophosphatemia, and immunosuppressive treatment regimen. Although bisphosphonates are useful in ameliorating bone mineral loss after transplantation, it is not known whether their use in renal transplant patients leads to excessive suppression of bone turnover and increased incidence of adynamic bone disease. A randomized, prospective, controlled, clinical trial was conducted using the bisphosphonate pamidronate intravenously in patients with new renal transplants. Treatment subjects (PAM) received pamidronate with vitamin D and calcium at baseline and at months 1, 2, 3, and 6. Control (CON) subjects received vitamin D and calcium only. During months 6 to 12, the subjects were observed without pamidronate treatment. Biochemical parameters of bone turnover were obtained monthly and, bone mineral density (BMD) was obtained at baseline and months 6 and 12. Bone biopsies for mineralized bone histology were obtained at baseline and at 6 mo in a subgroup of subjects who underwent scheduled living donor transplantation. PAM preserved bone mass at 6 and 12 mo as measured by bone densitometry and histomorphometry. CON had decreased vertebral BMD at 6 and 12 mo (4.8 ± 0.08 and 6.1 ± 0.09%, respectively). Biochemical parameters of bone turnover were similar in both groups at 6 and 12 mo. Bone histology revealed low turnover bone disease in 50% of the patients at baseline. At 6 mo, all of PAM had adynamic bone disease, whereas 50% of CON continued to have or developed decreased bone turnover. Pamidronate preserved vertebral BMD during treatment and 6 mo after cessation of treatment. Pamidronate treatment was associated with development of adynamic bone histology. Whether an improved BMD with adynamic bone histology is useful in maintaining long-term bone health in renal transplant recipients requires further study.

AB - Renal transplant recipients are at risk of developing bone abnormalities that result in bone loss and bone fractures. These are related to underlying renal osteodystrophy, hypophosphatemia, and immunosuppressive treatment regimen. Although bisphosphonates are useful in ameliorating bone mineral loss after transplantation, it is not known whether their use in renal transplant patients leads to excessive suppression of bone turnover and increased incidence of adynamic bone disease. A randomized, prospective, controlled, clinical trial was conducted using the bisphosphonate pamidronate intravenously in patients with new renal transplants. Treatment subjects (PAM) received pamidronate with vitamin D and calcium at baseline and at months 1, 2, 3, and 6. Control (CON) subjects received vitamin D and calcium only. During months 6 to 12, the subjects were observed without pamidronate treatment. Biochemical parameters of bone turnover were obtained monthly and, bone mineral density (BMD) was obtained at baseline and months 6 and 12. Bone biopsies for mineralized bone histology were obtained at baseline and at 6 mo in a subgroup of subjects who underwent scheduled living donor transplantation. PAM preserved bone mass at 6 and 12 mo as measured by bone densitometry and histomorphometry. CON had decreased vertebral BMD at 6 and 12 mo (4.8 ± 0.08 and 6.1 ± 0.09%, respectively). Biochemical parameters of bone turnover were similar in both groups at 6 and 12 mo. Bone histology revealed low turnover bone disease in 50% of the patients at baseline. At 6 mo, all of PAM had adynamic bone disease, whereas 50% of CON continued to have or developed decreased bone turnover. Pamidronate preserved vertebral BMD during treatment and 6 mo after cessation of treatment. Pamidronate treatment was associated with development of adynamic bone histology. Whether an improved BMD with adynamic bone histology is useful in maintaining long-term bone health in renal transplant recipients requires further study.

UR - http://www.scopus.com/inward/record.url?scp=10744232811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744232811&partnerID=8YFLogxK

U2 - 10.1097/01.ASN.0000087092.53894.80

DO - 10.1097/01.ASN.0000087092.53894.80

M3 - Article

C2 - 14514747

AN - SCOPUS:10744232811

VL - 14

SP - 2669

EP - 2676

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 10

ER -